PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia

Francis J. Giles*, Alan F. List, Michael Carroll, Jorge E. Cortes, Joyce Valickas, Bee Lian Chen, Eric Masson, Christian Jacques, Dirk Laurent, Maher Albitar, Eric J. Feldman, Gail J. Roboz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Angiogenesis is part of the pathophysiology of myelofibrosis with myeloid metaplasia (MMM). PTK787/ZK 222584 (PTK/ZK) is a novel inhibitor of vascular endothelial growth factor receptors. Twenty-nine patients with MMM received a continuous dosing schedule of PTK/ZK doses of 500 or 750 mg twice daily (BID). Transient potentially PTK/ZK related mild nausea, vomiting, dizziness, fatigue, thrombocytopenia, or anorexia occurred in 15% of patients. Dose limiting toxicities of dyspepsia, proteinurea, and/or mucositis were observed in patients treated with 750 mg BID. One (3%) and five (17%) patients achieved complete remission and clinical improvement, respectively. PTK/ZK has modest activity in patients with MMM.

Original languageEnglish (US)
Pages (from-to)891-897
Number of pages7
JournalLeukemia Research
Volume31
Issue number7
DOIs
StatePublished - Jul 2007

Keywords

  • Angiogenesis
  • Myelofibrosis
  • Tyrosine kinase inhibitor
  • VEGF

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia'. Together they form a unique fingerprint.

Cite this